JOB OFFER		
REFERENCE	**OPENING DATE**	**DEADLINE**
2020.302	**25/08/2023**	**03/09/2023**

PROFILE REQUIREMENTS	
EXCLUSIVE REQUIREMENTS: (1)	
ACADEMIC DEGREE	Specialist in Clinical Pharmacology *(Exclusive requirement: justification must be provided with the application).*
VALUED MERITS /SKYLLS	
EXPERIENCE	• Support for the conduct of clinical oncology trials in all their phases • Database management • Experience in monitoring and data management in clinical trials, especially in early phase trials. • Experience in the design and implementation of research projects. • Experience working in multidisciplinary biomedical research groups. • Experience advising and contributing to the training of technical staff of the group.

CONTRACT INFORMATION		
TYPE OF CONTRACT	**EXPECTED INCORPORATION DATE**	**JOB STATUS**
Indefinite in accordance with Article 23 Bis of Law 14/2011, of June 1, 2011, on Science, Technology and Innovation.	**September**	**Complete (40 h/week)**

ANNUAL GROSS SALARY	DURATION OF THE CONTRACT
48.895,64€	**Indefinite, linked to the duration of the project and economic availability based on RDL8/2022**
WORK LOCATIONS	**UNIT/DEPARTMENT**
Valdecilla South Building, 2nd Floor, Oncology Clinic	**Medical Oncology Service. HUMV**

JOB DETAILS
OFFER DESCRIPTION
Research support technician
FUNCTIONS
• **Collection of data from medical records, obtaining informed consent.** • **Management of databases for statistical analysis.** • **Analysis of results** • **Manuscript writing in English.** • **Assessment of patient inclusion criteria for inclusion in the trial.** • **Assessment of toxicities and dose adjustment.** • **Elaboration of protocols for investigational product administration and handling.** • **Support in monitoring, pharmacovigilance and data collection. Resolution of doubts of the monitoring staff** • **Communication with the international team to solve incidences.**

PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
Fernando Rivera Herrero	**Medical oncology**	**2023.123: A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) Phase 2, randomized, open-label study of botensilimab (AGEN1181) in monotherapy and in combination with balstilimab (AGEN2034) or investigator's choice of reference therapy (regorafenib or trifluridine and tipiracil) for the treatment of resistant metastatic colorectal cancer.**

RECRUITMENT INFORMATION	
SELECTION PROCESS STAGES (2)	**EMPLOYMENT EXCHANGE**
1. Pre-selection **2. Interview: minimum score for this phase: 45.** **3. Report of the Selection Board** **4. Resolution**	**NOT**

SELECTION BOARD

- **Fernando Rivera Herrero, Project´s Main Researcher**
- **Galo Peralta, IDIVAL´s Management Director**
- **Patricia Álvarez-Ingelmo, IDIVAL Human Resources Coordinator (She will act as registrar of the selection board).**

VALUATION OF MERITS

MERITS	EVALUATION	SCORE		MAXIMUM
Support for the conduct of clinical oncology trials in all their phases	Curriculum	Compliance with the requirement	YES / NOT	10
Database management	Curriculum	Compliance with the requirement	YES / NOT	10
Experience in monitoring and data management in clinical trials, especially in early phase trials.	Curriculum	Compliance with the requirement	YES / NOT	10
Experience in the design and implementation of research projects.	Curriculum	Compliance with the requirement	YES / NOT	10
Experience working in multidisciplinary biomedical research groups.	Curriculum	Compliance with the requirement	YES / NOT	10
Experience advising and contributing to the training of technical staff of the group.	Curriculum	Compliance with the requirement	YES / NOT	10

FINAL SCORE	
MAXIMUM TOTAL SCORE BY MERITS	**60**
MAXIMUM TOTAL SCORE IN INTERVIEW	**40**
MAXIMUM TOTAL SCORE	**100**

(1) Not subsanable
(2) See duration of each phase in the document "Selection Process"